KI-Beratung Beta

  • Produktbild: Molecular Biology of Neurodegenerative Diseases
  • Produktbild: Molecular Biology of Neurodegenerative Diseases
Band 168

Molecular Biology of Neurodegenerative Diseases Visions for the Future

169,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

20.11.2019

Herausgeber

David B. Teplow

Verlag

Elsevier Science & Technology

Seitenzahl

410

Maße (L/B/H)

22,9/15,2/2,4 cm

Gewicht

717 g

Sprache

Englisch

ISBN

978-0-12-817874-4

Beschreibung

Portrait

David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid ?-protein (Alzheimer's disease) and ?-synuclein (Parkinson's disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

20.11.2019

Herausgeber

David B. Teplow

Verlag

Elsevier Science & Technology

Seitenzahl

410

Maße (L/B/H)

22,9/15,2/2,4 cm

Gewicht

717 g

Sprache

Englisch

ISBN

978-0-12-817874-4

EU-Ansprechpartner

Elsevier B.V.
Radarweg 29
1043 NX Amsterdam
NL
productsafety@elsevier.com

Herstelleradresse

Elsevier Science & Technology
London Wall 125
EC2Y 5AS London
GB
tradeorders@elsevier.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Die Leseprobe wird geladen.
  • Produktbild: Molecular Biology of Neurodegenerative Diseases
  • Produktbild: Molecular Biology of Neurodegenerative Diseases
  • Section I: TARGETTING AD

    1. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings

    Kaj Blennow and Henrik Zetterberg

    2. Tracking down a missing trigger for Alzheimer's disease by mass spectrometric imaging based on brain network analysis

    Minako Hoshi

    3. Using mirror-image peptides to enhance robustness and reproducibility in studying the amyloid ß-protein

    Ariel J. Kuhn and Jevgenij A. Raskatov

    Section II: ETIOLOGY OF AD

    4. In search of pathogenic amyloid ß-peptide in familial Alzheimer's disease

    Michael S. Wolfe

    5. Biology of splicing in Alzheimer's disease research

    Kenichi Nagata, Takashi Saito, Takaomi C. Saido and Takashi Morihara

    6. Acquired cerebral amyloid angiopathy: An emerging concept

    Masahito Yamada, Tsuyoshi Hamaguchi and Kenji Sakai

    Section III: NEUROIMMUNOLOGY OF AD

    7. Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease

    Goran Šimi¿, Ena Špani¿, Lea Langer Horvat and Patrick R. Hof

    8. Gut microbiota mediated allostasis prevents stress-induced neuroinflammatory risk factors of Alzheimer's disease

    Susan Westfall, Umar Iqbal, Maria Sebastian and Giulio Maria Pasinetti

    9. Neuroimmune interactions in Alzheimer's disease-New frontier with old challenges?

    Stefan Prokop, Virginia M.Y. Lee and John Q. Trojanowski

    Section IV: AD THERAPY

    10. Alzheimer's therapy development: A few points to consider

    Einar M. Sigurdsson

    11. The next steps in curing Alzheimer's disease

    Fred W. van Leeuwen

    12. Future horizons in Alzheimer's disease research

    Thomas Wisniewski and Eleanor Drummond

    13. Why delay in effective treatment for Alzheimer's disease and related conditions

    Khalid Iqbal, Fei Liu, ChengXin Gong, Chunling Dai and Wen Hu

    14. Restoring synaptic function through multimodal therapeutics

    Raul Loera-Valencia, Muhammad-Al-Mustafa Ismail, Per Nilsson and Bengt Winblad

    15. Disease-modifying therapy for proteinopathies: Can the exception become the rule?

    Gal Bitan

    16. Combination therapy for Alzheimer's disease and related dementias

    Martin M. Bednar

    Section V: ALPHA-SYNUCLEINOPATHIES

    17. Can infections trigger alpha-synucleinopathies?

    Christopher T. Tulisiak, Gabriela Mercado, Wouter Peelaerts, Lena Brundin and Patrik Brundin

    18. Prion-like propagation of ¿-synuclein in neurodegenerative diseases

    Airi Tarutani and Masato Hasegawa

    Section VI: MODEL SYSTEMS

    19. Yeast models of neurodegenerative diseases

    Mick F. Tuite